- Managed three clinical stage programs, including a registrational program for Farber disease, a Phase 2 program for cystic fibrosis, and a Phase 2 program for melioidosis.- Successfully led the Farber program to clinical hold release submission, the cystic fibrosis program to site activation, and the melioidosis program through interim readout.- Worked closely with teams and vendors to ensure timely progress towards goals and mitigate risks, such as collaborating with the CMC team and CDMOs to streamline timelines and minimize risks during COVID-related supply chain issues in the Farber program.- Led a team in developing the clinical protocol for Farber disease, using my analysis of natural history data to steer the team towards selecting primary and secondary endpoints.- Analyzed market dynamics for multiple potential BD opportunities, including convincing management and the board of directors to pursue a cystic fibrosis BD opportunity by demonstrating that improvements in formulary coverage could make it feasible.- Served as the primary point of contact for investors' diligence efforts, enabling Aceragen to raise money through a reverse merger with Idera.

- Led teams analyzing competitive market dynamics for companies in the cancer, immunology, gene/cell therapy, ophthalmology, and other spaces, with clients including five of the top ten pharmaceutical companies.- Utilized a range of data, including public filings, clinical trial information, competitor medical and marketing materials, and interviews with key opinion leaders, to develop actionable strategies for clients to "win."- Worked with a client with a commercial immunology product to determine how competitor medical affairs messaging could be counteracted and monitored competitor clinical trials to determine whether research timelines needed to be accelerated to maintain first-mover advantage.- Aided clients in rationalizing their business development decisions, such as working with a research-stage ophthalmology product client to determine whether partnerships with diagnostic companies would enhance their commercial package.

- Performed due diligence reviews on various drugs to help clients develop investment packages and value their assets

- Led non-clinical research efforts at IVERIC, including projects to create a novel drug-delivery device and a sustained release formulation.- Successfully led sustained release formulation development through animal tox experiments and drug delivery device development through prototyping.- Authored and managed medical writing of non-clinical regulatory documents, including NDA non-clinical sections, IB non-clinical sections, and regulatory agency inquiries.- Analyzed data from CROs producing the novel drug-delivery device and delayed release formulation to determine whether the results were in line with IVERIC's needs.- Monitored profiles of the sustained release formulation and worked with the CRO to get the product back in line with the proposed specs when the release profile fell outside IVERIC's TPP.- Led due diligence efforts to assess technologies to support IVERIC's pipeline, including evaluating a bifunctional antibody drug for neovascular age-related macular degeneration, a sustained release formulation, and an ocular drug-delivery device.

- Determined the probability of success for the scientific, regulatory, and commercial viability of various entrepreneurial opportunities.

-Determined the substrate specificity of the HDAC8 enzyme using in vitro kinetic assays.-Developed kinetic assays to measure the HDAC specificity.-Wrote and edited sections of an NIH R01 grant -Managed collaborations with computational and experimental labs to develop models for HDAC substrate specificity

- Developed an assay to investigate the chemical stability of antibody drugs.

- Expressed and crystallized propionate kinase (a protein essential to the bioterrorism threat tularemia), and aided in refinement of its crystal structure.

- Identified how interactions between mitochondrial proteins affect fusion and fission using molecular biology and microscopy.

- Investigated protein-protein interaction using phage display libraries.